Shanghai Henlius Biotech Doses First Patient in Phase 1 Global Trial of HLX15-SC for Newly Diagnosed Multiple Myeloma in China 1
Shanghai Henlius Biotech: Key Developments in HLX15-SC Clini...
Sign in to continue:
Shanghai Henlius Biotech: Key Developments in HLX15-SC Clini...
InSilico Medicine to Join Hang Seng Biotech Index – Key Upda...
TOMO Holdings Limited: Supplemental Announcement on Property...
Great Harvest Maeta Holdings Limited Announces Periodical Up...
RemeGen Co., Ltd. Announces Discloseable Transaction: Purcha...
Transcenta Announces Receipt of HiCB Out-Licensing Milestone...
Softcare Limited: Controlling Shareholder Increases Stake—Ke...
Shandong Boan Biotechnology Announces Major New Indication A...
Hong Kong Food Investment Holdings Announces Major Asset Sal...
Hong Kong Food Investment Holdings Limited Proposes Major Di...